{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:51:24Z","timestamp":1793299884889,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Metabolic-associated steatohepatitis (MASH) and pancreatic inflammation are key complications of obesity-related metabolic syndrome. Elevated IL-6; a proinflammatory cytokine, contributes to liver steatosis and pancreatic \u03b2-islet cells dysfunction. This study explores pancreatic tissue-resident (tr)NK cells IL-6 receptor (IL-6R) in pancreatic injury in a murine MASH model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methodology<\/jats:title><jats:p>MASH models were established using male <jats:italic>Ob\/Ob<\/jats:italic> mice fed a high-fat diet (<jats:italic>Ob\/Ob<\/jats:italic><jats:sup>HFD<\/jats:sup>; 60.3% kcal from fat) for 4\u00a0weeks and using immunocompromised NOD-SCID IL2r\u03b3null (NSG) mice fed with HFD for 16\u00a0weeks and <jats:italic>i.v.<\/jats:italic> injected with 10 \u00d7 10<jats:sup>6<\/jats:sup> pancreatic trNK and treated with IL-6R antagonizing antibody on week 12. Biochemical assays assessed serum ALT, AST, lipids, glucose, and insulin levels. Pancreatic injury was analyzed through mRNA expression of Reg1, Reg3, oxidative stress marker of tissue malondialdehyde (MDA) and \u03b2\u2212islet cells\u2019 proliferation and apoptosis. Fibrotic markers of \u03b1-SMA, Collagen-I, and Fibronectin were assessed via RT-PCR and trNK cell activation (CD107a, NKp46, IFN-\u03b3) were assessed by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>Ob\/Ob<\/jats:italic><jats:sup>HFD<\/jats:sup> mice exhibited increased serum cholesterol, triglycerides, fasting blood glucose, and liver injury enzymes. Markers of pancreatic injury of Reg1\/Reg3 and pancreatic MDA with \u03b2\u2212islet cells apoptosis were significantly elevated compared to littermates\u2019 control. These results were accompanied by a decline in trNK counts and activations (P &amp;lt; 0.05). In an adoptive transfer model, NSG mice fed with HFD and transplanted with trNK cells from <jats:italic>Ob\/Ob<\/jats:italic><jats:sup>HFD<\/jats:sup> donors (expressing high IL-6) exhibited similar pancreatic injury markers, whereas those receiving trNK cells from <jats:italic>Ob\/Ob<\/jats:italic><jats:sup>HFD<\/jats:sup> mice pre-treated with an IL-6R antagonist showed marked reductions in Reg1\/Reg3 (\u223c2-fold), MDA (\u223c1.77-fold), and \u03b2-islet cells apoptosis (\u223c2.2-fold). Moreover, phenotypic characterization of the NSG mice fed an HFD transplanted with IL-6R antagonizing antibody showed an increase in the NK cell activation marker CD107a (\u223c2.3-fold) and amelioration in pancreatic fibrotic profile of \u03b1-SMA mRNA expressions of 1.6 -fold when compared to its counterparts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data highlights the importance of IL-6R modulation on trNK cells in remodeling pancreatic tissue after liver injury, emphasizing the liver-pancreas axis as a therapeutic target to prevent pancreatic damage, \u03b2-islet cells dysfunction and fibrosis and reduce the risk of diabetes and metabolic syndrome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1611637","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:27:36Z","timestamp":1751866056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Antagonizing IL-6 receptor restores pancreatic tissue resident NK cells activation and ameliorates pancreatic injury in the mouse model of MASH"],"prefix":"10.3389","volume":"16","author":[{"given":"Johnny","family":"Amer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Abu","family":"Arra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Salhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Kayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Maali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Shweiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113885","DOI":"10.1016\/j.biopha.2022.113885","article-title":"Gundelia tournefortii inhibits hepatocellular carcinoma progression by lowering gene expression of the cell cycle and hepatocyte proliferation in immunodeficient mice","volume":"156","author":"Amer","year":"2022","journal-title":"Biomed. and Pharmacother. = Biomedecine and Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jbspin.2017.07.004","article-title":"Rheumatoid arthritis treated with tocilizumab in two patients with complicated chronic liver disease with portal hypertension","volume":"85","author":"Amouzougan","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/jleuko\/qiac020","article-title":"NOD-scid IL2r\u03b3null mice lacking TLR4 support human immune system development and the study of human-specific innate immunity","volume":"113","author":"Aryee","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.55563\/clinexprheumatol\/usddjr","article-title":"Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index","volume":"40","author":"Avouac","year":"2022","journal-title":"Clinical and Experimental Rheumatology"},{"key":"B4","first-page":"329","article-title":"Thirty-day oral exposure to acetamiprid induces biochemical and histological alterations in rat pancreas: protective effects of carnosine supplementation","volume-title":"Toxicology Mechanisms and Methods","author":"Benchikh","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bluher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2016.00128","article-title":"Regulation of natural killer cell function by STAT3","volume":"7","author":"Cacalano","year":"2016","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1038\/s41598-023-39178-3","article-title":"Reg family proteins contribute to inflammation and pancreatic stellate cells activation in chronic pancreatitis","volume":"13","author":"Chen","year":"2023","journal-title":"Scientific Reports"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.2337\/db23-0171","article-title":"IL-6 trans-signaling Is increased in diabetes, impacted by glucolipotoxicity, and associated with liver stiffness and fibrosis in Fatty liver disease","volume":"72","author":"Gunes","year":"2023","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17539447231182548","DOI":"10.1177\/17539447231182548","article-title":"MiR-21 and tocilizumab interactions improve COVID-19 myocarditis outcomes","volume":"17","author":"Hossein Heydari","year":"2023","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbrc.2023.02.032","article-title":"Hypoxia-inducible factor 1\u03b1\/IL-6 axis in activated hepatic stellate cells aggravates liver fibrosis","volume":"653","author":"Kou","year":"2023","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B17","article-title":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-","year":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0033024","DOI":"10.1128\/iai.00330-24","article-title":"Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection","volume":"93","author":"Mateu-Borr\u00e1s","year":"2025","journal-title":"Infect. Immun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"869414","DOI":"10.3389\/fendo.2022.869414","article-title":"Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic \u03b2 Cells","volume":"13","author":"Murakami","year":"2022","journal-title":"Frontiers in Endocrinology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Annals of the Eheumatic Diseases"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1590\/s0004-2803.202000000-27","article-title":"Pancreatic steatosis: a new diagnosis and therapeutic challenge in Gastroenterology","volume":"57","author":"Paul","year":"2020","journal-title":"Arquivos De Gastroenterologia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42358-023-00298-z","article-title":"Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis","volume":"63","author":"Pugliesi","year":"2023","journal-title":"Adv. Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4103\/ijccm.IJCCM_478_16","article-title":"Interleukin-6: an early predictive marker for severity of acute pancreatitis","volume":"21","author":"Rao","year":"2017","journal-title":"Indian J. Crit. care Med. peer-reviewed, official Publ. Indian Soc. Crit. Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.782","article-title":"The soluble interleukin 6 receptor: advanced therapeutic options in inflammation","volume":"102","author":"Rose-John","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.36849\/JDD.6532","article-title":"Tocilizumab treatment in COVID-19 patients: comparing cutaneous disease and adverse drug effects","volume":"22","author":"Rosenberg","year":"2023","journal-title":"J. drugs dermatology JDD"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Frontiers in Endocrinology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3906\/sag-2010-131","article-title":"Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies","volume":"51","author":"Sarfraz","year":"2021","journal-title":"Turkish J. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"947568","DOI":"10.3389\/fimmu.2022.947568","article-title":"The multifaceted role of STAT3 in NK-Cell tumor surveillance","volume":"13","author":"Witalisz-Siepracka","year":"2022","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic Inflammation and Insulin Resistance in Obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circulation Research"},{"key":"B15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jdi.13202","article-title":"Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic \u03b2-cell mass and function","volume":"11","author":"Yang","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/03009734.2015.1032453","article-title":"Activated pancreatic stellate cells can impair pancreatic islet function in mice","volume":"120","author":"Zang","year":"2015","journal-title":"Upsala journal of Medical Sciences"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1611637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:27:38Z","timestamp":1751866058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1611637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1611637"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1611637","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"article-number":"1611637"}}